Kheir, A.; Johannsdottir, B.; Grönn-Weiss, A.; Liu, L. L.; Ullén, A.; Laurell, A.; Håkansson, A.; Verbiené, I.; Ullenhag, G.; Carlhed, R. Baseline Laboratory Values and Metastatic Burden Predict Survival in Addition to IMDC Risk in Real-World Renal Cell Carcinoma Patients Treated With Ipilimumab-Nivolumab. AO 2025, 64, 1355-1364.